Last reviewed · How we verify

Nexrutine

The University of Texas Health Science Center at San Antonio · discontinued Small molecule

Nexrutine is a Small molecule drug developed by The University of Texas Health Science Center at San Antonio. It is currently in discontinued development. Also known as: bark extract of Phellodendron amurense.

At a glance

Generic nameNexrutine
Also known asbark extract of Phellodendron amurense
SponsorThe University of Texas Health Science Center at San Antonio
ModalitySmall molecule
Therapeutic areaOther
Phasediscontinued

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Nexrutine

What is Nexrutine?

Nexrutine is a Small molecule drug developed by The University of Texas Health Science Center at San Antonio.

Who makes Nexrutine?

Nexrutine is developed by The University of Texas Health Science Center at San Antonio (see full The University of Texas Health Science Center at San Antonio pipeline at /company/the-university-of-texas-health-science-center-at-san-antonio).

Is Nexrutine also known as anything else?

Nexrutine is also known as bark extract of Phellodendron amurense.

What development phase is Nexrutine in?

Nexrutine is in discontinued.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing